Market Overview

CAS Medical Surges As Edwards Lifesciences Agrees To Buy Medtech Company In $100M Deal

Share:
CAS Medical Surges As Edwards Lifesciences Agrees To Buy Medtech Company In $100M Deal
Related EW
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
58 Biggest Movers From Yesterday
Factors of Influence in —…–9, Key Indicators and Opportunity within ARRIS International ... (GuruFocus)
Related CASM
The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
58 Biggest Movers From Yesterday

CAS Medical Systems Inc (NASDAQ: CASM) shares are rising by one-half of their value Tuesday after Edwards Lifesciences Corp (NYSE: EW), a manufacturer of heart valves and other medical devices, announced an agreement to buy the company.

What Happened 

CAS Medical is a medical tech company that focuses on non-invasive monitoring of tissue oxygenation in the brain.

Edwards will buy CAS Medical in an all-cash transaction for $2.45 per share, or an equity value of about $100 million, according to the terms of the deal.

The per-share value represents a 56-percent premium over the $1.57 at which CAS Medical shares closed Monday.

Why It's Important 

"We believe the incorporation of CASMED's FORE-SIGHT technology into Edwards' leading hemodynamic monitoring platform, along with Edwards' predictive analytics capability, will strengthen Edwards' leadership in smart monitoring technologies by providing physicians with a more comprehensive status of their surgical and critically ill patients," Katie Szyman, Edwards' corporate vice president of critical care, said in a statement. 

The companies expect the transaction to close in the second quarter, subject to the satisfaction of customary closing conditions, including antitrust clearance and approval by CAS Medical shareholders.

What's Next

As a precondition to the deal, all holders of CAS Medical's Series A convertible preferred stock or Series A exchangeable preferred stock will convert their shares into common stock and will be eligible to receive the deal consideration due to common shareholders.

At last check, CAS Medical shares were rallying 54.14 percent to $2.42, their highest levels since mid-August. Edwards shares were also advancing, rising 1.36 percent to $175.66. 

Related Links:

FDA Panel Reviews Johnson & Johnson's Treatment-Resistant Depression Candidate: What To Expect

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Posted-In: medical devices MedtechNews Health Care M&A Trading Ideas General Best of Benzinga

 

Related Articles (CASM + EW)

View Comments and Join the Discussion!

EUR/USD Forecast: The Big Levels To Watch After It Lost The Triple Bottom

GBP/USD Forecast: After Meeting 1.2850 Target, 1.2800 Is Next Amid Brexit Stalemate